Dermatology

In this Q&A interview, Del Rosso discussed his presentation on eczema therapies, the updates he made to his conference presentations this year, as well as his outlook on future research.

Cases have increased annually; a clinician shares his strategy for remaining aggressive and diligent in prevention and management.

Secukinumab and bimekizumab may reach the market soon for the treatment of HS. What will it provide patients?

The cross-specialty collaboration between dermatologists and these fields has been a daily occurrence, as inflammation-targeting drugs and comorbid patients have brought team closer together.

Since roflumilast cream was approved by the FDA last July, one dermatology physician assistant advocates for its use as a primary medication.

The introduction of the TYK2 inhibitor is the latest advancement toward cross-specialty care with systemic agents.

Ahead of Fall Clinical Dermatology 2023 Conference for PAs & NPs, Glick discusses how the COVID-19 reshaped dermatology roles, and the value of physician assistants and nurse practitioners in the current care team.

Boni Elewski, MD, and Benjamin Kaffenberger, MD, and Carly Elston, MD, provide their recommendations for clinicians who are taking care of patients with rare dermatological disorders in the critical care setting.

Dermatological experts discuss challenges that are associated with the use of standard and emerging treatments in special patient population.

This new research indicates substantial detection of lower-risk disease among patients who are considered to be health-seeking.

These 4 treatments and their biosimilars show no significant differences, though future studies may be necessary to assess long-term efficacy and safety of biosimilars in treating psoriasis.

Andrew Blauvelt, MD, discusses switching therapies for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, discusses upadacitinib for the treatment of atopic dermatitis (AD).

A dermatology expert discusses taking a nuanced approach to interpreting the boxed warnings for JAK inhibitor for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).

Andrew Blauvelt, MD, provides an overview of different treatment options that are available for patients with moderate to severe atopic dermatitis (AD).

Christopher G. Bunick, MD, PhD, shares their clinical approach for switching therapies for atopic dermatitis (AD) treatment.

A dermatology expert provides an overview of the results of the meta-analysis data from the RAD 2023 atopic dermatitis (AD) trial.

Christopher G. Bunick, MD, PhD, discusses underutilized efficacy outcomes in atopic dermatitis (AD) clinical trials.

A dermatology expert discusses how numerical rating scale (NRS) is used in atopic dermatitis (AD) clinical trials.

For this interview segment, Dr. Arkin discussed the biggest points she hopes dermatologists will take away from National Scleroderma Awareness Month this year.

A dermatology expert discusses how the standard of care EASI scores have been improving with newer atopic dermatitis (AD) therapies.

Christopher G. Bunick, MD, PhD, provides an overview of clinical trial outcomes in atopic dermatitis (AD).

Christopher G. Bunick, MD, PhD, discusses what can be done to improve the standard of care for atopic dermatitis (AD).

Experts discuss how to improve recognition and referral for rare dermatologic conditions in the ER setting.